Syros Pharmaceuticals (SYRS) Misses Q2 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Syros Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
August 9, 2022 7:30 AM EDTPreliminary Data From First Cross-Over Study Directly Comparing PK of SY-2101 to the Approved IV Dose of ATO Demonstrates Comparable PK Exposures; Expect to Initiate Phase 3 Clinical Trial of SY-2101 in APL 2H 2023
Definitive Merger Agreement with TYME Technologies and Concurrent PIPE Expected to Close 2H 2022 and Bring Combined Proceeds of Approximately $190 Million, Extending Cash Runway into 2025
On Track to Report Data from Safety Lead-ins of the SELECT-AML-1 Trial and the Phase 1 SY-5609 Trial in Pancreatic Cancer in 2H 2022
Advanced SY-12882, an Oral,... More
